From Pharmacy Drug Guide
The FDA approved Simponi (golimumab) as a once-a-month, injectable therapy for adults suffering from three chronic, debilitating forms of arthritis. Simponi should be used with medical supervision. Simponi was designed to be used with methotrexate, an immunosuppressant, in patients with moderate to severe rheumatoid arthritis. Simponi can be combined with methotrexate to treat psoriatic arthritis. For patients with arthritis of the spine, or ankylosing spondylitis, Simponi alone can be used. Common side effects can be compared to those of a cold or the flu. A human antibody, Simponi targets and reduces the effects of too much tumor necrosis factor or TNF-alpha. Inflammatory diseases often cause the body to produce more of this protein than needed.
|Brand name for||Golimumab|
|Manufacturer||Johnson & Johnson|
|Uses||Treatment of chronic arthritis|
|Common side effects||Flu-like symptoms, upper respiratory infection|
|Who should not take Simponi||People who have TB or active infections|
|Disclaimer||The information provided by PharmacyDrugGuide is not a substitute for professional medical advice, diagnosis, or treatment. Do not take any action based on the information on this page without consulting a physician.|
Common Simponi Side Effects
Upper respiratory tract infections, scratchy throat, stuffy nose and reaction at the injection site are the common side effects.   Because Simponi can reduce blood cells that help fight infections, your physician may order frequent blood tests before you begin and again during treatment. Report all traditional signs of infection – fever, chills, stomach upset and/or achy muscles.
About Drug Side Effects
Simponi Allergic Reactions
The Simponi needle cover contains dry natural rubber which can produce an allergic reaction in patients with a sensitivity to rubber or latex.
Allergic reactions such as hives, swollen face, trouble breathing, chest pain, should be reported immediately to a doctor.
Simponi Precautions and Warnings
Before taking Simponi, patients should inform their doctor and pharmacist if they have or live with someone who has tuberculosis, or have recently traveled or plan to travel to areas where TB is common. People who are allergic to golimumab, or those who are currently using adalimumab (Humira), certolizumab (Cimzia), etanercept (Enbrel) or infliximab (Remicade) should not use Simponi. Several types of cancers, some fast-growing and fatal, have been reported in children and adolescent patients treated with TNF blockers like Simponi. People with active disease inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, may be more prone to contract lymphoma. Evidence on whether Simponi appears in breast milk or is absorbed by an infant systemically is not conclusive, so the decision to use Simponi while nursing should be made with medical guidance. Likewise, the safety and effectiveness of Simponi in children under 18 has not been established.